HGF as angiogenic factor and therapeutic approach

Current Signal Transduction Therapy

Volumn 6, Issue 2, 2011, Pages 221-227

  Taniyama, Yoshiaki ^a,b   Takeya, Yasushi ^a,b   Azuma, Junya ^a,b   Iekushi, Kazuma ^a,b   Sanada, Fumihiro ^a   Kusunoki, Hiroshi ^a,b   Okayama, Keita ^a   Koibuchi, Nobutaka ^a,c   Rakugi, Hiromi ^b   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis; Gene therapy; HGF; Peripheral artery disease (PAD); VEGF

Indexed keywords

ANGIOTENSIN II; PLACEBO; PLASMID DNA; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; ENDOTHELIUM CELL; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 79957960791     PISSN: 15743624     EISSN: 15743624     Source Type: Journal    
DOI: 10.2174/157436211795660016     Document Type: Article

References (42)

1. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3. (Pubitemid 19277521)
2. Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995; 373: 702-5.
3. Nakamura Y, Morishita R, Nakamura S, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 1996; 28: 409-13. (Pubitemid 26296043)
4. Nakamura Y, Morishita R, Higaki J, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996; 14: 1067-72. (Pubitemid 26329282)
5. Morishita R, Nakamura S, Nakamura Y, et al. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 1997; 46: 138-42. (Pubitemid 27009962)
6. Nakagami H, Morishita R, Yamamoto K, et al. Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes 2001; 50: 1472-81. (Pubitemid 32500182)
7. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77: 261-71. (Pubitemid 24138623)
8. Yo Y, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on epithelial cells. Kidney Int 1998; 54: 1128-38. (Pubitemid 28449899)
9. Yamamoto K, Morishita R, Hayashi S, et al. Contribution of Bcl-2, but not Bcl-xL and Bax, to antiapoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension 2001; 37: 1341-8. (Pubitemid 34163592)
10. Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/ hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol 1995; 15: 1110-22.
11. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994; 127: 1783-7.
12. Takaishi K, Sasaki T, Kato M, et al. Involvement of Rho p21 small GTP-binding protein and its regulator in the HGF-induced cell motility. Oncogene 1994; 9: 273-9. (Pubitemid 24020959)
13. Nakagami H, Morishita R, Yamamoto K, et al. Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. J Hypertens 2000; 18: 1411-20.
14. Nakamura Y, Morishita R, Higaki J, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 1995; 215: 483-8.
15. Van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998; 97: 381-90. (Pubitemid 28074339)
16. Hayashi S, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 1999; 100: II301-8. (Pubitemid 29523551)
17. Morishita R, Nakamura S, Hayashi S, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999; 33: 1379-84. (Pubitemid 29282658)
18. Silvagno F, Follenzi A, Arese M, et al. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 1857-65.
19. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95: 2552-8. (Pubitemid 27233121)
20. Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8: 181-9. (Pubitemid 32186129)
21. Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther 2006; 13: 1206-13. (Pubitemid 44184714)
22. Taniyama Y, Morishita R, Hiraoka K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001; 104: 2344-50. (Pubitemid 33049519)
23. Morishita R, Sakaki M, Yamamoto K, et al. Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation 2002; 105: 1491-6. (Pubitemid 34263283)
24. Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44: 203-9. (Pubitemid 39014240)
25. Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010; 17: 1152-61.
26. Rajagopalan S, Mohler ER, 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-8. (Pubitemid 37296537)
27. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a doubleblind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58-65.
28. Sanada F, Taniyama Y, Azuma J, et al. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension 2009; 53: 77-82.
29. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
30. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600. (Pubitemid 36204953)
31. Yu Y, Fukuda N, Yao EH, et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens 2008; 21: 72-7.
32. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-6. (Pubitemid 35396976)
33. Sanada F, Taniyama Y, Iekushi K, et al. Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ Res 2009; 105: 667-75.
34. Pesesse X, Deleu S, De Smedt F, Drayer L, Erneux C. Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem Biophys Res Commun 1997; 239: 697-700. (Pubitemid 27504164)
35. Vandenbroere I, Paternotte N, Dumont JE, Erneux C, Pirson I. The c-Cbl-associated protein and c-Cbl are two new partners of the SH2-containing inositol polyphosphate 5-phosphatase SHIP2. Biochem Biophys Res Commun 2003; 300: 494-500. (Pubitemid 38375836)
36. Prasad NK, Decker SJ. SH2-containing 5'-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J Biol Chem 2005; 280: 13129-36.
37. Soubeyran P, Kowanetz K, Szymkiewicz I, et al. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 2002; 416: 183-7. (Pubitemid 34246476)
38. Kowanetz K, Szymkiewicz I, Haglund K, et al. Identification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors. J Biol Chem 2003; 278: 39735-46. (Pubitemid 37248535)
39. Kowanetz K, Husnjak K, Holler D, et al. CIN85 associates with multiple effectors controlling intracellular trafficking of epidermal growth factor receptors. Mol Biol Cell 2004; 15: 3155-66. (Pubitemid 38850113)
40. Yoshitomi Y, Kojima S, Umemoto T, et al. Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Clin Endocrinol Metab 1999; 84: 2425-8.
41. Nakamura S, Morishita R, Moriguchi A, et al. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J Hypertens 1998; 16: 2019-26. (Pubitemid 29002383)
42. Nakamura S, Moriguchi A, Morishita R, et al. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun 1998; 242: 238-43. (Pubitemid 28412409)